Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Diabetes Mellitus, Type 2 | 88 | 2022 | 12252 | 2.410 |
Why?
|
Hypoglycemic Agents | 34 | 2021 | 3110 | 1.760 |
Why?
|
Life Style | 36 | 2021 | 3931 | 1.440 |
Why?
|
Weight Loss | 23 | 2020 | 2720 | 1.180 |
Why?
|
Metformin | 23 | 2020 | 909 | 1.150 |
Why?
|
Prediabetic State | 12 | 2021 | 548 | 1.030 |
Why?
|
Fluorocarbons | 8 | 2021 | 506 | 0.900 |
Why?
|
Blood Glucose | 28 | 2021 | 6434 | 0.840 |
Why?
|
Cardiovascular Diseases | 23 | 2022 | 15662 | 0.720 |
Why?
|
Alkanesulfonic Acids | 5 | 2021 | 203 | 0.710 |
Why?
|
Environmental Pollutants | 8 | 2021 | 1290 | 0.700 |
Why?
|
Exercise | 22 | 2022 | 5953 | 0.660 |
Why?
|
Glucagon-Like Peptide 1 | 3 | 2013 | 374 | 0.650 |
Why?
|
Glucose Intolerance | 10 | 2020 | 579 | 0.640 |
Why?
|
Cyclohexanes | 6 | 2013 | 152 | 0.610 |
Why?
|
Insulin | 20 | 2014 | 6610 | 0.590 |
Why?
|
Diabetic Angiopathies | 12 | 2019 | 806 | 0.570 |
Why?
|
Muscle Proteins | 7 | 1999 | 1165 | 0.570 |
Why?
|
Phenylalanine | 6 | 2013 | 368 | 0.560 |
Why?
|
Monosaccharide Transport Proteins | 9 | 2001 | 437 | 0.550 |
Why?
|
Overweight | 11 | 2021 | 2445 | 0.520 |
Why?
|
Thiazolidinediones | 8 | 2013 | 461 | 0.490 |
Why?
|
Diabetes Mellitus | 20 | 2017 | 5892 | 0.490 |
Why?
|
Endothelium, Vascular | 15 | 2013 | 4428 | 0.480 |
Why?
|
Obesity | 27 | 2021 | 13087 | 0.470 |
Why?
|
Glucose | 8 | 2011 | 4352 | 0.430 |
Why?
|
Diabetes Mellitus, Type 1 | 8 | 2015 | 3447 | 0.360 |
Why?
|
Muscle, Skeletal | 12 | 2017 | 4980 | 0.360 |
Why?
|
Risk Reduction Behavior | 6 | 2020 | 1119 | 0.360 |
Why?
|
Insulin Resistance | 9 | 2021 | 3982 | 0.340 |
Why?
|
Caprylates | 3 | 2019 | 115 | 0.330 |
Why?
|
Hyperglycemia | 6 | 2010 | 1389 | 0.330 |
Why?
|
Chromans | 4 | 2005 | 116 | 0.320 |
Why?
|
Technology, Pharmaceutical | 1 | 2007 | 84 | 0.270 |
Why?
|
Dietary Proteins | 1 | 2011 | 960 | 0.250 |
Why?
|
Endocrine Disruptors | 2 | 2019 | 264 | 0.250 |
Why?
|
Blood Pressure | 11 | 2020 | 8541 | 0.240 |
Why?
|
Diabetes Mellitus, Experimental | 5 | 2002 | 1124 | 0.240 |
Why?
|
Vasodilation | 7 | 2014 | 967 | 0.230 |
Why?
|
Brachial Artery | 6 | 2014 | 373 | 0.220 |
Why?
|
Adipose Tissue | 4 | 2014 | 3335 | 0.210 |
Why?
|
Humans | 123 | 2022 | 768887 | 0.210 |
Why?
|
Glucose Transporter Type 4 | 7 | 1999 | 241 | 0.200 |
Why?
|
Middle Aged | 78 | 2021 | 223740 | 0.200 |
Why?
|
Comprehensive Health Care | 2 | 2015 | 123 | 0.200 |
Why?
|
Valine | 4 | 2013 | 410 | 0.190 |
Why?
|
Caloric Restriction | 3 | 2018 | 301 | 0.190 |
Why?
|
Adiponectin | 5 | 2015 | 1117 | 0.190 |
Why?
|
Male | 89 | 2021 | 365249 | 0.190 |
Why?
|
Physical Fitness | 3 | 2016 | 744 | 0.190 |
Why?
|
Cholesterol, HDL | 4 | 2016 | 1820 | 0.190 |
Why?
|
Islets of Langerhans | 2 | 2004 | 1351 | 0.180 |
Why?
|
Islets of Langerhans Transplantation | 4 | 2002 | 748 | 0.180 |
Why?
|
Lipids | 4 | 2019 | 3345 | 0.180 |
Why?
|
Body Weight | 7 | 2020 | 4628 | 0.180 |
Why?
|
Female | 83 | 2021 | 397464 | 0.170 |
Why?
|
Microcirculation | 9 | 2004 | 1281 | 0.170 |
Why?
|
Behavior Therapy | 2 | 2017 | 886 | 0.170 |
Why?
|
Body Mass Index | 15 | 2021 | 13054 | 0.160 |
Why?
|
Triglycerides | 6 | 2016 | 2464 | 0.160 |
Why?
|
Angiotensin II Type 1 Receptor Blockers | 3 | 2010 | 428 | 0.160 |
Why?
|
Glucose Transporter Type 1 | 5 | 1996 | 186 | 0.160 |
Why?
|
Dyslipidemias | 3 | 2016 | 873 | 0.160 |
Why?
|
Drug Therapy, Combination | 9 | 2013 | 6320 | 0.150 |
Why?
|
Adiposity | 4 | 2020 | 1895 | 0.150 |
Why?
|
Diet, Reducing | 4 | 2015 | 487 | 0.150 |
Why?
|
Thiazoles | 3 | 2003 | 1542 | 0.150 |
Why?
|
Diet | 6 | 2020 | 8090 | 0.150 |
Why?
|
Risk Factors | 32 | 2021 | 74971 | 0.150 |
Why?
|
Tetrazoles | 4 | 2013 | 923 | 0.140 |
Why?
|
Dioxoles | 1 | 1997 | 96 | 0.140 |
Why?
|
Patient Care Team | 1 | 2008 | 2527 | 0.140 |
Why?
|
Skin | 7 | 2004 | 4507 | 0.140 |
Why?
|
Sulfonylurea Compounds | 1 | 1998 | 220 | 0.140 |
Why?
|
Aging | 2 | 2015 | 8765 | 0.130 |
Why?
|
Fasting | 6 | 2012 | 1610 | 0.130 |
Why?
|
Time | 1 | 2018 | 552 | 0.130 |
Why?
|
Peripheral Vascular Diseases | 1 | 2019 | 489 | 0.130 |
Why?
|
Receptor, Melanocortin, Type 4 | 1 | 2017 | 131 | 0.130 |
Why?
|
Aged | 43 | 2021 | 171790 | 0.130 |
Why?
|
Depression | 4 | 2019 | 8240 | 0.130 |
Why?
|
Antidepressive Agents | 3 | 2019 | 2914 | 0.130 |
Why?
|
Glucose Metabolism Disorders | 1 | 2016 | 52 | 0.130 |
Why?
|
Adult | 51 | 2022 | 223818 | 0.130 |
Why?
|
Triazoles | 2 | 2013 | 904 | 0.130 |
Why?
|
Adrenergic beta-Agonists | 1 | 1997 | 347 | 0.130 |
Why?
|
Pyrazines | 2 | 2013 | 1206 | 0.130 |
Why?
|
Natriuretic Peptide, Brain | 3 | 2021 | 1751 | 0.120 |
Why?
|
Double-Blind Method | 12 | 2015 | 12469 | 0.120 |
Why?
|
Fatty Liver | 1 | 2021 | 810 | 0.120 |
Why?
|
Glucose Tolerance Test | 5 | 2013 | 1183 | 0.120 |
Why?
|
Placebos | 6 | 2013 | 1668 | 0.110 |
Why?
|
Blood Glucose Self-Monitoring | 2 | 2015 | 475 | 0.110 |
Why?
|
Dietary Carbohydrates | 2 | 2017 | 896 | 0.110 |
Why?
|
Growth Hormone | 1 | 1996 | 573 | 0.110 |
Why?
|
Dietary Fiber | 1 | 2017 | 767 | 0.110 |
Why?
|
Energy Intake | 3 | 2017 | 2146 | 0.110 |
Why?
|
Follow-Up Studies | 15 | 2021 | 39394 | 0.110 |
Why?
|
Patient Education as Topic | 6 | 2017 | 2339 | 0.110 |
Why?
|
Vasculitis | 2 | 2007 | 525 | 0.100 |
Why?
|
Brain-Derived Neurotrophic Factor | 1 | 2017 | 607 | 0.100 |
Why?
|
Calcinosis | 1 | 2021 | 1481 | 0.100 |
Why?
|
Receptors, Glucagon | 1 | 2013 | 90 | 0.100 |
Why?
|
Hypertrophy, Left Ventricular | 1 | 2018 | 856 | 0.100 |
Why?
|
Self Report | 2 | 2022 | 3773 | 0.100 |
Why?
|
Biological Transport | 5 | 1999 | 2085 | 0.100 |
Why?
|
Heptanoic Acids | 2 | 2004 | 344 | 0.100 |
Why?
|
Speech Perception | 1 | 2017 | 512 | 0.100 |
Why?
|
Incretins | 1 | 2012 | 100 | 0.100 |
Why?
|
Environmental Exposure | 3 | 2017 | 4538 | 0.090 |
Why?
|
Oxidants, Photochemical | 1 | 2011 | 77 | 0.090 |
Why?
|
Incidence | 11 | 2019 | 21545 | 0.090 |
Why?
|
Gastric Emptying | 1 | 2013 | 247 | 0.090 |
Why?
|
Diuretics | 1 | 2013 | 614 | 0.090 |
Why?
|
Genetic Loci | 2 | 2017 | 2630 | 0.090 |
Why?
|
Calcium Channel Blockers | 1 | 2013 | 691 | 0.090 |
Why?
|
Statistics as Topic | 2 | 2015 | 2359 | 0.090 |
Why?
|
Venoms | 1 | 2010 | 94 | 0.080 |
Why?
|
Edema | 2 | 2004 | 766 | 0.080 |
Why?
|
Cross-Sectional Studies | 11 | 2021 | 26384 | 0.080 |
Why?
|
Disease Progression | 5 | 2017 | 13677 | 0.080 |
Why?
|
Iontophoresis | 4 | 2002 | 75 | 0.080 |
Why?
|
Testosterone | 2 | 2016 | 2494 | 0.080 |
Why?
|
Health Services | 1 | 2014 | 755 | 0.080 |
Why?
|
Motor Cortex | 1 | 2017 | 1014 | 0.080 |
Why?
|
Aortic Valve Stenosis | 1 | 2021 | 2034 | 0.080 |
Why?
|
Hydroxymethylglutaryl-CoA Reductase Inhibitors | 3 | 2013 | 3253 | 0.080 |
Why?
|
Diabetes Complications | 3 | 2011 | 1320 | 0.080 |
Why?
|
Air Pollutants | 2 | 2014 | 2905 | 0.080 |
Why?
|
United States | 14 | 2021 | 73180 | 0.080 |
Why?
|
Insulin Infusion Systems | 1 | 2010 | 221 | 0.080 |
Why?
|
Polymorphism, Single Nucleotide | 4 | 2016 | 16051 | 0.080 |
Why?
|
Internationality | 1 | 2013 | 1008 | 0.070 |
Why?
|
Neuronal Plasticity | 1 | 2017 | 1449 | 0.070 |
Why?
|
Hormones, Ectopic | 2 | 2004 | 37 | 0.070 |
Why?
|
Diabetes, Gestational | 2 | 2014 | 1260 | 0.070 |
Why?
|
Ozone | 1 | 2011 | 496 | 0.070 |
Why?
|
Pyrroles | 2 | 2004 | 1126 | 0.070 |
Why?
|
Adrenergic beta-Antagonists | 1 | 2013 | 1243 | 0.070 |
Why?
|
Vascular Cell Adhesion Molecule-1 | 4 | 2008 | 692 | 0.070 |
Why?
|
Exercise Test | 3 | 2013 | 2187 | 0.070 |
Why?
|
Cell Membrane | 5 | 1999 | 3659 | 0.070 |
Why?
|
Sex Hormone-Binding Globulin | 2 | 2020 | 554 | 0.070 |
Why?
|
Cognition | 3 | 2020 | 7080 | 0.070 |
Why?
|
Treatment Outcome | 12 | 2020 | 65485 | 0.070 |
Why?
|
Adenosine Deaminase Inhibitors | 1 | 2007 | 9 | 0.070 |
Why?
|
Diabetic Nephropathies | 2 | 2013 | 973 | 0.070 |
Why?
|
Postprandial Period | 2 | 2007 | 320 | 0.070 |
Why?
|
Particulate Matter | 2 | 2011 | 2607 | 0.070 |
Why?
|
Drug Design | 1 | 2012 | 1046 | 0.070 |
Why?
|
Cerebrovascular Circulation | 1 | 2017 | 2736 | 0.070 |
Why?
|
Postpartum Period | 1 | 2014 | 1198 | 0.070 |
Why?
|
Hemoglobin A | 1 | 2007 | 84 | 0.070 |
Why?
|
PPAR alpha | 1 | 2008 | 177 | 0.070 |
Why?
|
Dipeptidyl Peptidase 4 | 1 | 2007 | 93 | 0.070 |
Why?
|
Intercellular Adhesion Molecule-1 | 2 | 2007 | 1133 | 0.070 |
Why?
|
Gastric Inhibitory Polypeptide | 1 | 2007 | 69 | 0.070 |
Why?
|
Intercellular Signaling Peptides and Proteins | 2 | 2004 | 1658 | 0.070 |
Why?
|
Plasminogen Activator Inhibitor 1 | 1 | 2007 | 279 | 0.070 |
Why?
|
Cognition Disorders | 1 | 2020 | 3985 | 0.070 |
Why?
|
Tyrosine | 2 | 2002 | 1427 | 0.070 |
Why?
|
Rats | 10 | 2002 | 23847 | 0.070 |
Why?
|
Polymorphism, Genetic | 3 | 2012 | 4251 | 0.070 |
Why?
|
Peptide Fragments | 2 | 2021 | 5150 | 0.070 |
Why?
|
Cholesterol, LDL | 3 | 2016 | 2402 | 0.060 |
Why?
|
Rats, Sprague-Dawley | 5 | 1998 | 8200 | 0.060 |
Why?
|
Self Care | 2 | 2008 | 801 | 0.060 |
Why?
|
Disease Susceptibility | 3 | 2007 | 1794 | 0.060 |
Why?
|
Diabetic Neuropathies | 2 | 2001 | 410 | 0.060 |
Why?
|
Hypotension | 1 | 2011 | 888 | 0.060 |
Why?
|
Nitroglycerin | 2 | 2004 | 332 | 0.060 |
Why?
|
Cohort Studies | 9 | 2019 | 41800 | 0.060 |
Why?
|
Kidney | 4 | 2021 | 7057 | 0.060 |
Why?
|
Heart Rate | 2 | 2012 | 4217 | 0.060 |
Why?
|
PPAR gamma | 1 | 2008 | 487 | 0.060 |
Why?
|
Fractures, Bone | 1 | 2017 | 2063 | 0.060 |
Why?
|
Drugs, Investigational | 1 | 2007 | 213 | 0.060 |
Why?
|
Electrocardiography | 1 | 2018 | 6413 | 0.060 |
Why?
|
Administration, Oral | 1 | 2012 | 4042 | 0.060 |
Why?
|
Hormones | 2 | 2010 | 871 | 0.060 |
Why?
|
Diabetic Retinopathy | 1 | 2013 | 1299 | 0.060 |
Why?
|
Cholesterol | 2 | 2019 | 2913 | 0.060 |
Why?
|
Body Composition | 1 | 2013 | 2461 | 0.060 |
Why?
|
Diuresis | 1 | 2004 | 107 | 0.060 |
Why?
|
Lipid Metabolism | 1 | 2012 | 1904 | 0.060 |
Why?
|
Ketosis | 1 | 2003 | 46 | 0.060 |
Why?
|
Blood Circulation | 1 | 2005 | 248 | 0.060 |
Why?
|
Calcium | 1 | 2017 | 5792 | 0.060 |
Why?
|
Heart Failure | 3 | 2021 | 11879 | 0.060 |
Why?
|
Leukocyte Count | 1 | 2007 | 1609 | 0.060 |
Why?
|
Homocysteine | 1 | 2006 | 637 | 0.050 |
Why?
|
Anti-Inflammatory Agents | 1 | 2013 | 1813 | 0.050 |
Why?
|
Antihypertensive Agents | 1 | 2013 | 2026 | 0.050 |
Why?
|
Creatinine | 1 | 2008 | 1917 | 0.050 |
Why?
|
Dipeptidyl-Peptidase IV Inhibitors | 1 | 2007 | 317 | 0.050 |
Why?
|
Predictive Value of Tests | 4 | 2015 | 15471 | 0.050 |
Why?
|
Microvessels | 2 | 2019 | 586 | 0.050 |
Why?
|
Proportional Hazards Models | 5 | 2017 | 12563 | 0.050 |
Why?
|
Cardiovascular System | 1 | 2010 | 840 | 0.050 |
Why?
|
Tumor Suppressor Proteins | 1 | 2012 | 2813 | 0.050 |
Why?
|
Acetylcholine | 5 | 2002 | 629 | 0.050 |
Why?
|
Vitamin D Deficiency | 1 | 2011 | 1388 | 0.050 |
Why?
|
Tissue Plasminogen Activator | 1 | 2007 | 1165 | 0.050 |
Why?
|
Prospective Studies | 7 | 2020 | 54950 | 0.050 |
Why?
|
Metabolic Diseases | 1 | 2008 | 684 | 0.050 |
Why?
|
Eating | 2 | 2000 | 1542 | 0.050 |
Why?
|
Tumor Necrosis Factor-alpha | 3 | 2008 | 4356 | 0.050 |
Why?
|
Insulin-Secreting Cells | 1 | 2009 | 899 | 0.050 |
Why?
|
Absorptiometry, Photon | 1 | 2007 | 1757 | 0.050 |
Why?
|
Risk | 2 | 2012 | 9621 | 0.050 |
Why?
|
CD40 Ligand | 1 | 2003 | 528 | 0.050 |
Why?
|
Glycogen | 1 | 2002 | 252 | 0.050 |
Why?
|
Health Care Costs | 1 | 2014 | 3270 | 0.050 |
Why?
|
Linear Models | 3 | 2019 | 5890 | 0.050 |
Why?
|
Hypoglycemia | 2 | 2009 | 895 | 0.050 |
Why?
|
Regression Analysis | 4 | 2014 | 6346 | 0.050 |
Why?
|
Cell Cycle Proteins | 1 | 2012 | 3450 | 0.040 |
Why?
|
Poly(ADP-ribose) Polymerases | 1 | 2002 | 428 | 0.040 |
Why?
|
Aged, 80 and over | 6 | 2017 | 59738 | 0.040 |
Why?
|
Multivariate Analysis | 2 | 2013 | 12093 | 0.040 |
Why?
|
Motor Activity | 2 | 2015 | 2722 | 0.040 |
Why?
|
Time Factors | 9 | 2020 | 40266 | 0.040 |
Why?
|
Carrier Proteins | 1 | 2013 | 4940 | 0.040 |
Why?
|
C-Reactive Protein | 3 | 2007 | 3858 | 0.040 |
Why?
|
Nervous System | 1 | 2003 | 547 | 0.040 |
Why?
|
Vitamin E | 1 | 2005 | 874 | 0.040 |
Why?
|
Nitroprusside | 4 | 2002 | 272 | 0.040 |
Why?
|
Water | 2 | 2004 | 1421 | 0.040 |
Why?
|
Kidney Diseases | 1 | 2011 | 2100 | 0.040 |
Why?
|
Minority Groups | 1 | 2007 | 1216 | 0.040 |
Why?
|
Energy Metabolism | 2 | 2003 | 2905 | 0.040 |
Why?
|
Oxygen Consumption | 2 | 2004 | 1883 | 0.040 |
Why?
|
Blood Vessels | 1 | 2005 | 1110 | 0.040 |
Why?
|
Blood Flow Velocity | 1 | 2003 | 1376 | 0.040 |
Why?
|
5'-Nucleotidase | 2 | 1999 | 164 | 0.040 |
Why?
|
Glycoproteins | 1 | 2007 | 2202 | 0.040 |
Why?
|
Vasomotor System | 1 | 1999 | 208 | 0.040 |
Why?
|
Animals | 13 | 2020 | 169408 | 0.040 |
Why?
|
Blood Coagulation | 1 | 2005 | 1161 | 0.040 |
Why?
|
Reflex | 1 | 2001 | 375 | 0.040 |
Why?
|
Prevalence | 4 | 2019 | 15875 | 0.040 |
Why?
|
Cell Fractionation | 1 | 1999 | 247 | 0.040 |
Why?
|
Obesity, Morbid | 1 | 2010 | 1300 | 0.040 |
Why?
|
Feeding Behavior | 1 | 2011 | 3206 | 0.040 |
Why?
|
Societies, Medical | 1 | 2011 | 3967 | 0.040 |
Why?
|
Risk Assessment | 8 | 2016 | 24330 | 0.040 |
Why?
|
Inflammation | 3 | 2008 | 10869 | 0.040 |
Why?
|
Kinetics | 2 | 1996 | 6334 | 0.040 |
Why?
|
Nutrition Surveys | 2 | 2021 | 1738 | 0.040 |
Why?
|
Peptides | 1 | 2010 | 4353 | 0.040 |
Why?
|
Vitamin D | 1 | 2011 | 3311 | 0.040 |
Why?
|
Patient Compliance | 1 | 2008 | 2701 | 0.040 |
Why?
|
Particle Size | 2 | 2016 | 1652 | 0.040 |
Why?
|
Sex Characteristics | 1 | 2008 | 2660 | 0.040 |
Why?
|
Coronary Artery Disease | 1 | 2017 | 6569 | 0.040 |
Why?
|
Calcium-Calmodulin-Dependent Protein Kinases | 1 | 1998 | 492 | 0.030 |
Why?
|
Proteins | 2 | 2010 | 6011 | 0.030 |
Why?
|
Glucose Clamp Technique | 1 | 1997 | 263 | 0.030 |
Why?
|
JNK Mitogen-Activated Protein Kinases | 1 | 1998 | 440 | 0.030 |
Why?
|
Boston | 4 | 2014 | 9375 | 0.030 |
Why?
|
Seafood | 1 | 2020 | 395 | 0.030 |
Why?
|
Seasons | 2 | 2014 | 1523 | 0.030 |
Why?
|
Regional Blood Flow | 3 | 2005 | 1502 | 0.030 |
Why?
|
Hypertension | 3 | 2011 | 8615 | 0.030 |
Why?
|
Mental Status Schedule | 1 | 2017 | 315 | 0.030 |
Why?
|
C-Peptide | 1 | 1998 | 443 | 0.030 |
Why?
|
Cell Adhesion Molecules | 2 | 1999 | 1614 | 0.030 |
Why?
|
Heredity | 1 | 2016 | 149 | 0.030 |
Why?
|
Clinical Trials as Topic | 3 | 2007 | 8055 | 0.030 |
Why?
|
Biological Transport, Active | 1 | 1996 | 323 | 0.030 |
Why?
|
Temperature | 2 | 2014 | 2235 | 0.030 |
Why?
|
Forearm | 3 | 2004 | 428 | 0.030 |
Why?
|
Arteries | 1 | 2021 | 1126 | 0.030 |
Why?
|
Phlorhizin | 1 | 1995 | 37 | 0.030 |
Why?
|
Randomized Controlled Trials as Topic | 3 | 2020 | 10397 | 0.030 |
Why?
|
Inflammation Mediators | 1 | 2004 | 1890 | 0.030 |
Why?
|
Mitogen-Activated Protein Kinase Kinases | 1 | 1998 | 637 | 0.030 |
Why?
|
Fatty Acids, Nonesterified | 1 | 1997 | 394 | 0.030 |
Why?
|
Cell Compartmentation | 1 | 1996 | 383 | 0.030 |
Why?
|
Transcription Factors | 2 | 2013 | 12174 | 0.030 |
Why?
|
Hand Strength | 1 | 2018 | 466 | 0.030 |
Why?
|
Epididymis | 1 | 1997 | 227 | 0.030 |
Why?
|
Body Size | 1 | 2018 | 463 | 0.030 |
Why?
|
Leisure Activities | 2 | 2008 | 310 | 0.030 |
Why?
|
Treatment Failure | 2 | 2013 | 2663 | 0.030 |
Why?
|
Leptin | 1 | 2003 | 1597 | 0.030 |
Why?
|
Streptozocin | 1 | 1995 | 190 | 0.030 |
Why?
|
Receptor, Insulin | 1 | 1999 | 838 | 0.030 |
Why?
|
Epinephrine | 1 | 1998 | 794 | 0.030 |
Why?
|
DNA-Binding Proteins | 1 | 2012 | 9618 | 0.030 |
Why?
|
Reference Values | 4 | 2004 | 4941 | 0.030 |
Why?
|
Solubility | 3 | 2003 | 1087 | 0.030 |
Why?
|
von Willebrand Factor | 3 | 2006 | 680 | 0.030 |
Why?
|
Nutrition Assessment | 1 | 2017 | 740 | 0.030 |
Why?
|
Genotype | 3 | 2013 | 13048 | 0.030 |
Why?
|
Quality-Adjusted Life Years | 1 | 2020 | 1741 | 0.030 |
Why?
|
Weight Gain | 3 | 2014 | 2359 | 0.030 |
Why?
|
Research Design | 3 | 2019 | 6213 | 0.030 |
Why?
|
Evoked Potentials, Motor | 1 | 2017 | 465 | 0.030 |
Why?
|
Genetic Predisposition to Disease | 4 | 2017 | 18065 | 0.030 |
Why?
|
Resistin | 2 | 2004 | 172 | 0.030 |
Why?
|
Vasodilator Agents | 3 | 2004 | 990 | 0.030 |
Why?
|
Rats, Inbred Lew | 3 | 2002 | 1163 | 0.030 |
Why?
|
Diet, Fat-Restricted | 1 | 2015 | 328 | 0.030 |
Why?
|
Estrogen Replacement Therapy | 1 | 1999 | 1209 | 0.030 |
Why?
|
Prognosis | 3 | 2021 | 30044 | 0.030 |
Why?
|
Axons | 1 | 2001 | 1678 | 0.030 |
Why?
|
Humidity | 1 | 2014 | 207 | 0.030 |
Why?
|
Quality of Life | 1 | 2014 | 13510 | 0.030 |
Why?
|
Hyperinsulinism | 1 | 1995 | 402 | 0.030 |
Why?
|
Nutritional Physiological Phenomena | 1 | 1994 | 360 | 0.030 |
Why?
|
Hypertriglyceridemia | 1 | 1995 | 293 | 0.020 |
Why?
|
Indian Ocean | 1 | 2011 | 13 | 0.020 |
Why?
|
Indians, North American | 2 | 2007 | 354 | 0.020 |
Why?
|
Tissue Distribution | 1 | 1996 | 2299 | 0.020 |
Why?
|
Anti-Inflammatory Agents, Non-Steroidal | 1 | 2002 | 2277 | 0.020 |
Why?
|
Ventricular Function, Left | 1 | 2005 | 3941 | 0.020 |
Why?
|
Liposomes | 1 | 1995 | 792 | 0.020 |
Why?
|
Blotting, Western | 1 | 1999 | 5035 | 0.020 |
Why?
|
Electromyography | 1 | 2017 | 1402 | 0.020 |
Why?
|
Neoplasms | 1 | 2020 | 22390 | 0.020 |
Why?
|
Air Pollution | 1 | 2005 | 2367 | 0.020 |
Why?
|
Kaplan-Meier Estimate | 2 | 2013 | 6546 | 0.020 |
Why?
|
Models, Biological | 1 | 2007 | 9499 | 0.020 |
Why?
|
Single-Blind Method | 1 | 2014 | 1585 | 0.020 |
Why?
|
Hyperlipidemias | 1 | 1995 | 773 | 0.020 |
Why?
|
Genetic Markers | 1 | 2016 | 2604 | 0.020 |
Why?
|
Aspirin | 1 | 2002 | 3135 | 0.020 |
Why?
|
Morbidity | 1 | 1995 | 1757 | 0.020 |
Why?
|
Smoking | 1 | 2006 | 9094 | 0.020 |
Why?
|
Health Education | 1 | 2016 | 1059 | 0.020 |
Why?
|
Dietary Fats | 1 | 2017 | 2003 | 0.020 |
Why?
|
Preventive Health Services | 1 | 2014 | 568 | 0.020 |
Why?
|
Phosphatidylinositol 3-Kinases | 1 | 1999 | 2884 | 0.020 |
Why?
|
Interviews as Topic | 1 | 2017 | 2742 | 0.020 |
Why?
|
Hypolipidemic Agents | 1 | 2013 | 609 | 0.020 |
Why?
|
Biopsy | 2 | 2002 | 6805 | 0.020 |
Why?
|
Drug Administration Schedule | 1 | 2017 | 4862 | 0.020 |
Why?
|
Safety | 2 | 2004 | 1159 | 0.020 |
Why?
|
Basal Metabolism | 1 | 2010 | 163 | 0.020 |
Why?
|
Psychiatric Status Rating Scales | 1 | 2019 | 6031 | 0.020 |
Why?
|
Albuminuria | 2 | 2005 | 658 | 0.020 |
Why?
|
Cytokines | 1 | 2003 | 7453 | 0.020 |
Why?
|
Endothelins | 1 | 2008 | 127 | 0.020 |
Why?
|
Longitudinal Studies | 3 | 2003 | 14795 | 0.020 |
Why?
|
Models, Statistical | 2 | 2013 | 5107 | 0.020 |
Why?
|
Health Planning Guidelines | 1 | 2008 | 153 | 0.020 |
Why?
|
Lipoproteins | 1 | 2012 | 880 | 0.020 |
Why?
|
Methylglycosides | 1 | 1987 | 10 | 0.020 |
Why?
|
Cost-Benefit Analysis | 1 | 2020 | 5544 | 0.020 |
Why?
|
Methylglucosides | 1 | 1987 | 35 | 0.020 |
Why?
|
Health Status | 2 | 2013 | 4095 | 0.020 |
Why?
|
Swine | 1 | 1997 | 5998 | 0.020 |
Why?
|
Social Support | 1 | 2017 | 2193 | 0.020 |
Why?
|
Injections | 1 | 2010 | 841 | 0.020 |
Why?
|
Transcranial Magnetic Stimulation | 1 | 2017 | 1489 | 0.020 |
Why?
|
Retrospective Studies | 1 | 2015 | 81892 | 0.020 |
Why?
|
Depressive Disorder | 1 | 2019 | 3726 | 0.020 |
Why?
|
Liver | 1 | 2002 | 7579 | 0.020 |
Why?
|
Myocardium | 1 | 1999 | 4790 | 0.020 |
Why?
|
Program Evaluation | 1 | 2014 | 2507 | 0.020 |
Why?
|
Albumins | 1 | 2008 | 577 | 0.020 |
Why?
|
Coronary Vessels | 1 | 2017 | 3124 | 0.020 |
Why?
|
Disease Management | 1 | 2016 | 2537 | 0.020 |
Why?
|
Quantitative Trait Loci | 1 | 2013 | 2133 | 0.020 |
Why?
|
Foot | 2 | 2001 | 577 | 0.020 |
Why?
|
Dose-Response Relationship, Drug | 1 | 1997 | 10778 | 0.020 |
Why?
|
Hot Temperature | 1 | 2011 | 1440 | 0.020 |
Why?
|
RNA-Binding Proteins | 1 | 2013 | 1891 | 0.010 |
Why?
|
Pregnancy | 3 | 2014 | 30175 | 0.010 |
Why?
|
Sulfates | 1 | 2005 | 379 | 0.010 |
Why?
|
Child | 3 | 2010 | 80969 | 0.010 |
Why?
|
Adolescent | 3 | 2010 | 89247 | 0.010 |
Why?
|
Kidney Cortex | 1 | 2004 | 168 | 0.010 |
Why?
|
Case-Control Studies | 3 | 2013 | 22294 | 0.010 |
Why?
|
Combined Modality Therapy | 1 | 2015 | 8559 | 0.010 |
Why?
|
Neuropsychological Tests | 1 | 2017 | 7148 | 0.010 |
Why?
|
Kidney Medulla | 1 | 2004 | 169 | 0.010 |
Why?
|
Amino Acids | 1 | 2010 | 1716 | 0.010 |
Why?
|
Gene Expression | 1 | 1996 | 7602 | 0.010 |
Why?
|
Thyroxine-Binding Proteins | 1 | 1983 | 24 | 0.010 |
Why?
|
Logistic Models | 1 | 2018 | 13317 | 0.010 |
Why?
|
Glyburide | 1 | 2003 | 117 | 0.010 |
Why?
|
Genetic Association Studies | 1 | 2012 | 2747 | 0.010 |
Why?
|
Retinol-Binding Proteins | 1 | 1983 | 67 | 0.010 |
Why?
|
Protein Biosynthesis | 1 | 2010 | 2094 | 0.010 |
Why?
|
Vasoconstriction | 1 | 2005 | 593 | 0.010 |
Why?
|
Blood Volume | 1 | 2003 | 546 | 0.010 |
Why?
|
Glucose-6-Phosphate | 1 | 2002 | 29 | 0.010 |
Why?
|
Magnetic Resonance Spectroscopy | 1 | 2012 | 3782 | 0.010 |
Why?
|
Glycogen Synthase | 1 | 2002 | 62 | 0.010 |
Why?
|
Spain | 1 | 2003 | 485 | 0.010 |
Why?
|
Transferrin | 1 | 1983 | 284 | 0.010 |
Why?
|
Carbon | 1 | 2005 | 672 | 0.010 |
Why?
|
Laser-Doppler Flowmetry | 1 | 2002 | 238 | 0.010 |
Why?
|
Vascular Resistance | 1 | 2004 | 939 | 0.010 |
Why?
|
Alleles | 1 | 2012 | 6901 | 0.010 |
Why?
|
RNA, Messenger | 1 | 1996 | 12809 | 0.010 |
Why?
|
Genetic Variation | 1 | 2015 | 6610 | 0.010 |
Why?
|
Nitric Oxide Synthase | 1 | 2002 | 911 | 0.010 |
Why?
|
Sodium Chloride | 1 | 2002 | 584 | 0.010 |
Why?
|
Nitric Oxide Synthase Type III | 1 | 2002 | 706 | 0.010 |
Why?
|
Educational Status | 1 | 2007 | 2515 | 0.010 |
Why?
|
Sex Distribution | 1 | 2004 | 2280 | 0.010 |
Why?
|
Receptor, EphA8 | 1 | 1998 | 4 | 0.010 |
Why?
|
Probability | 1 | 2004 | 2483 | 0.010 |
Why?
|
Young Adult | 3 | 2010 | 60110 | 0.010 |
Why?
|
Arteriosclerosis | 1 | 2003 | 1056 | 0.010 |
Why?
|
Age Distribution | 1 | 2004 | 2875 | 0.010 |
Why?
|
Signal Transduction | 2 | 1999 | 23652 | 0.010 |
Why?
|
Receptors, Cytoplasmic and Nuclear | 1 | 2003 | 859 | 0.010 |
Why?
|
Phenotype | 1 | 2016 | 16735 | 0.010 |
Why?
|
MAP Kinase Kinase 4 | 1 | 1998 | 147 | 0.010 |
Why?
|
Ribosomal Protein S6 Kinases | 1 | 1998 | 203 | 0.010 |
Why?
|
Endothelin-1 | 1 | 1999 | 296 | 0.010 |
Why?
|
Socioeconomic Factors | 1 | 2011 | 7860 | 0.010 |
Why?
|
Patient Selection | 1 | 2010 | 4265 | 0.010 |
Why?
|
Phosphorylation | 2 | 1999 | 8317 | 0.010 |
Why?
|
Genome-Wide Association Study | 1 | 2017 | 12798 | 0.010 |
Why?
|
Insulin Receptor Substrate Proteins | 1 | 1999 | 558 | 0.010 |
Why?
|
Enzyme Activation | 1 | 2002 | 3588 | 0.010 |
Why?
|
Stroke | 1 | 2019 | 9756 | 0.010 |
Why?
|
Receptors, Immunologic | 1 | 2002 | 1418 | 0.010 |
Why?
|
Analysis of Variance | 1 | 2004 | 6242 | 0.010 |
Why?
|
Premenopause | 1 | 1999 | 1039 | 0.010 |
Why?
|
Neurologic Examination | 1 | 1997 | 916 | 0.010 |
Why?
|
Sex Factors | 1 | 2008 | 10641 | 0.010 |
Why?
|
Magnetic Resonance Imaging | 2 | 2017 | 36861 | 0.010 |
Why?
|
Cell Nucleus | 1 | 2002 | 2885 | 0.010 |
Why?
|
Interleukin-6 | 1 | 2003 | 3233 | 0.010 |
Why?
|
Nutritional Requirements | 1 | 1994 | 279 | 0.010 |
Why?
|
Pregnancy in Diabetics | 1 | 1994 | 198 | 0.010 |
Why?
|
Acute Disease | 1 | 2003 | 7245 | 0.010 |
Why?
|
Oxygen | 1 | 2004 | 4273 | 0.010 |
Why?
|
Ultrasonography | 1 | 2005 | 6001 | 0.010 |
Why?
|
Severity of Illness Index | 1 | 2010 | 15955 | 0.010 |
Why?
|
Protein Kinases | 1 | 1998 | 1611 | 0.010 |
Why?
|
Age Factors | 1 | 2008 | 18454 | 0.010 |
Why?
|
Physical Examination | 1 | 1997 | 1262 | 0.010 |
Why?
|
Receptor Protein-Tyrosine Kinases | 1 | 1998 | 1629 | 0.010 |
Why?
|
Postmenopause | 1 | 1999 | 2519 | 0.010 |
Why?
|
Phosphoproteins | 1 | 1999 | 2452 | 0.010 |
Why?
|
Pilot Projects | 1 | 2003 | 8742 | 0.010 |
Why?
|
Comorbidity | 1 | 2003 | 10591 | 0.000 |
Why?
|
Immunohistochemistry | 1 | 2002 | 11119 | 0.000 |
Why?
|
Intracellular Signaling Peptides and Proteins | 1 | 1999 | 2892 | 0.000 |
Why?
|
Algorithms | 1 | 2009 | 14199 | 0.000 |
Why?
|
Health Behavior | 1 | 2000 | 2649 | 0.000 |
Why?
|
Chronic Disease | 1 | 2003 | 9384 | 0.000 |
Why?
|
3-O-Methylglucose | 1 | 1987 | 37 | 0.000 |
Why?
|
Nucleotidases | 1 | 1987 | 29 | 0.000 |
Why?
|
Cytochalasin B | 1 | 1987 | 74 | 0.000 |
Why?
|
NADH Dehydrogenase | 1 | 1987 | 47 | 0.000 |
Why?
|
Massachusetts | 1 | 2000 | 8888 | 0.000 |
Why?
|
Heart Diseases | 1 | 2000 | 2819 | 0.000 |
Why?
|
Microsomes | 1 | 1987 | 252 | 0.000 |
Why?
|
Rats, Inbred Strains | 1 | 1987 | 2087 | 0.000 |
Why?
|
Galactosyltransferases | 1 | 1987 | 284 | 0.000 |
Why?
|
Mice | 1 | 2008 | 82074 | 0.000 |
Why?
|
Prealbumin | 1 | 1983 | 259 | 0.000 |
Why?
|
Protein Binding | 1 | 1983 | 9344 | 0.000 |
Why?
|